A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

To learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL.

Start Date28 Mar 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06124157 / Not yet recruitingPhase 3IIT

A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia

This phase III trial compares the effect of the combination of blinatumomab with dasatinib and standard chemotherapy versus dasatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or Philadelphia chromosome-like (Ph-Like) ABL-class B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib and chemotherapy alone.

Start Date28 Feb 2025

Sponsor / Collaborator

National Cancer Institute

NCT04199026 / Not yet recruitingEarly Phase 1IIT

Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas

This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.

Start Date31 Jan 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Doxorubicin Hydrochloride

100 Translational Medicine associated with Doxorubicin Hydrochloride

100 Patents (Medical) associated with Doxorubicin Hydrochloride

16,873

Literatures (Medical) associated with Doxorubicin Hydrochloride

01 Feb 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Engineering small extracellular vesicles with multivalent DNA probes for precise tumor targeting and enhanced synergistic therapy

Article

Author: Ma, Ruo-Fei ; Zhang, Qi ; Ren, Xiu-Yan ; Xu, Zhang-Run ; Ren, Ting-Ju

Small extracellular vesicles (sEVs) have gained wide attention as efficient carriers for disease treatment. However, the proclivity of sEVs to be ingested by source cells is insufficient to accurately target specific sites, posing a challenge in realizing controlled targeting treatment. Here, we developed an engineered sEV nanocarrier capable of precise tumor targeting and enhanced synergistic therapy. Multivalent DNA probes, comprising abundant AS1411 aptamers and telomerase primers, were innovatively modified on the sEV membrane (M-D-sEV) for precise tumor targeting. To achieve synergistic therapy, gold nanorod-cerium oxide nanostructures (Au NRs-CeO₂) and manganese dioxide nanosheets-doxorubicin (MnO₂ NSs-DOX) were encapsulated into liposomes (Lip-Mat). Then M-D-sEV and Lip-Mat were fused together through membrane fusion to obtain nanocarriers. Owing to the multivalence of the probes, the surface of the nanocarriers was loaded with numerous aptamers, which greatly enhances their targeting ability and promotes the accumulation of drugs. When nanocarriers were ingested by tumor cells, telomerase and multivalent DNA probes triggered their aggregation, enhancing the therapeutic effect. Furthermore, under laser irradiation, Au NRs-CeO₂ converted light into hyperthermia, thereby inducing the destruction of nanocarriers membrane. This process initiated a series of reactions involving glutathione and H₂O₂ consumption, as well as DOX release, ultimately achieving synergistic tumor therapy. In vitro and in vivo studies demonstrated the remarkable targeting ability of multivalent DNA probes and excellent therapeutic effect of this strategy. The engineered strategy of sEVs provide a promising approach for precise tumor therapy and hold great potential for the development of efficient, safe, and personalized drug delivery systems.

13 Jan 2025·NANOTECHNOLOGY

Doxorubicin-loaded methoxy-intercalated kaolinite as a repackaging of doxorubicin for an enhanced breast cancer treatment: in vitro and in vivo investigation

Article

Author: Sayed, Fatma Al-Zahraa ; Mohamed, Ayman S ; Fahmy, Heba Mohamed

Abstract:

Doxorubicin (Dox) is one of the most common wide-spectrum chemotherapeutics. However, its efficacy is limited due to off-target accumulation and selectivity issues. In this study, we compared the anti-cancer effect and biocompatibility of KaoliniteMeOH-Dox (KMD), a Dox repackaging, to Dox monotherapy. The formulation was extensively tested using transmission electron microscopy, dynamic light scattering, zeta potential, Fourier transform infrared, x-ray diffraction, and in vitro drug release. The MTT assay measured MCF-7 cell growth inhibition in vitro. In vivo testing involved 20 naïve mice and 40 Ehrlich solid tumor-inoculated mice. The tumor size was monitored for 18 d. In all experimental groups, tumor and cardiac tissues were evaluated for cytotoxicity and genotoxicity by addressing oxidative stress, histopathology, and comet assay. We found that KMD has many advantages in terms of size, charge, shape, high loading efficiency (90.16%), and pH-dependent release. The MTT assay showed that the formulation outperformed Dox in growth inhibition and selectivity. In vivo, research showed that KMD suppressed tumors by 86.075% compared to 60.379% for free Dox. Histological analysis showed that KMD reduced tumor size, metastasis, and carcinogenic oxidative stress and inflammation in mice without harming naive mice. Based on the obtained data, the KMD formulation holds promise for breast cancer treatment and warrants further investigation.

01 Jan 2025·BRAIN BEHAVIOR AND IMMUNITY

Dietary EPA and DHA enrichment of a high fat diet during doxorubicin-based chemotherapy attenuated neuroinflammatory gene expression in the brain of C57bl/6 ovariectomized mice

Article

Author: Orchard, Tonya S ; Melink, Zihan ; Courtney DeVries, A ; Ziouzenkova, Ouliana ; Emmers, Katie ; Belury, Martha A ; Ormiston, Kate ; Murphy, Kelly ; Andridge, Rebecca ; Lustberg, Maryam

Chemotherapy agents in breast cancer are associated with chemotherapy-related cognitive impairments (CRCI). Mechanisms are not fully clear, but alterations of glucose and lipid metabolism, neuroinflammation and neurodegeneration may contribute to CRCI. The aim of this study was to investigate the combined effects of a high fat (HF) diet combined with doxorubicin-based chemotherapy on glucose and lipid metabolism, neuroinflammation, and neurodegeneration in mice. Additionally, we examined the therapeutic potential of dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to attenuate these effects. Female C57Bl/6 mice (n = 42) were fed HF, HFn-3 (2 % kcals as EPA + DHA) or Low Fat (LF) diets for seven weeks, with and without chemotherapy. In this study, two chemotherapy injections led to weight and body fat loss associated with a decrease in insulin resistance measured by HOMA-IR. HOMA-IR was significantly greater in HF versus LF groups; but HOMA-IR in HFn-3 group did not significantly differ from either HF or LF groups. Chemotherapy resulted in higher brain concentrations of the inflammatory chemokine KC/GRO. Compared to LF diet plus chemotherapy, HF diet plus chemotherapy upregulated multiple genes involved in neuroinflammation and neurodegeneration pathways. HFn-3 diet plus chemotherapy attenuated gene expression by downregulating multiple genes involved in neuroinflammation and blood brain barrier regulation, including Mapkapk2, Aqp4, and s100b, and upregulating Kcnb1 and Atxn3, genes involved in reduction of oxidative stress and anxiety, respectively. Overall, a HF diet combined with chemotherapy is associated with neuroinflammatory and neurodegenerative gene expression changes in this mouse model; dietary enrichment of EPA and DHA attenuated these effects. Further studies are needed to understand how diet impacts behavioral outcomes of CRCI.

307

News (Medical) associated with Doxorubicin Hydrochloride

24 Oct 2024

·www.globenewswire.com

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona LONDON – Oct. 24, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces scientific presentations of two novel programs in its pipeline at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The presentations include data from two preclinical oncology assets, AVA6103 and AVA7100, from Avacta’s pipeline of pre|CISION® product candidates. Both presentations take place today in the Antibody Drug Conjugate (ADC) poster session at the Symposium. Avacta’s pre|CISION® product candidates are designed to be activated specifically in the tumor microenvironment (TME), thereby enabling improved antitumor activity while reducing systemic toxicities. Each peptide drug conjugate (PDC) in the Company’s pipeline is comprised of an active antitumor drug (known as a payload) linked to the pre|CISION peptide, which renders the payload inert and is cleaved only within the tumor by the action of Fibroblast Activation Protein, or FAP, expressed in the cancer associated fibroblasts in the TME. The pre|CISION® technology addresses key limitations of ADCs, namely (1) non-specific payload release that results in significant off target toxicities, and (2) the complexity of the bystander effect, which is necessary to target antigen-negative tumor cells and thus to treat antigen-low populations. The pre|CISION platform addresses these limitations by releasing payload only in the tumor microenvironment and optimizing the bystander mechanism of action. AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development. AVA7100 is a part of a new class of pre|CISION®-enabled Affimer® drug conjugates with potential applications in multiple cancer types, including those with lower levels of FAP in the tumor. AVA6103 and AVA7100 are expected to enter IND-enabling studies in late 2024 and 2H 2025, respectively. The details of these advances in the pre|CISION® technology are presented below. Christina Coughlin, MD PhD, CEO of Avacta, commented: “We are encouraged by the preclinical data from AVA6103 demonstrating that FAP-enabled exatecan induces DNA damage and drives cancer cell death and we look forward to advancing this promising therapy toward the clinic. The preliminary data from AVA7100 demonstrating that exposure to Affimer® Drug Conjugates (AffDCs) results in drug cleavage, release of the payload and tumor cell kill as a bystander function are exciting for this entirely new class of therapies. “These presentations showcase the evolution of our pre|CISION® platform technology to selectively deliver highly potent payloads directly to the TME, while minimizing exposure in normal tissues and optimizing patients’ outcomes. Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models. With the advances in the platform, we are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic. Potent topoisomerase I inhibitors are the payloads of ADC therapies in the clinic, although the non-specific release of these payloads can lead to severe off-target toxicities. Given the lack of these toxicities in our first program and the broad reach of the topoisomerase I inhibitor class, we see our next programs as having great potential for true impact in patients with high unmet need.” AVA6103 Results In a poster titled “The novel peptide drug conjugate AVA6103 is a FAP-enabled pre|CISION® medicine which targets Topoisomerase I to the tumor microenvironment via FAP cleavage” in vivo data were presented that demonstrate the ability to target and accumulate the active warhead in the tumor microenvironment, resulting in tumor growth inhibition with AVA6103. Specifically, the key findings from the poster demonstrate: The therapeutic index of exatecan is significantly increased by pre|CISION enabling, specifically the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimenAVA6103 optimizes the bystander effect where the conjugate is only cleaved by FAP-positive fibroblasts, and released exatecan can enter FAP-negative cancer cellsHigh intratumoral warhead concentrations are seen at 4hr and 24hr timepoints for several pre|CISION exatecan compounds, with up to 50-fold higher warhead concentrations in the tumor versus plasma in a patient-derived xenograft model, AVA6103 inhibits tumor growth, with complete responses noted in a preclinical treated model engineered with human FAP expression (HEK-FAP) tumors. Increased survival was also shown in this model treated with AVA6103 compared with other models with vehicle-treated tumors. AVA7100 Results A poster titled “Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the pre|CISION® release mechanism” include data demonstrating that exposure of tumor cell line or fibroblast cell co-cultures to AffDCs results in drug cleavage, release of the warhead and tumor cell kill as a bystander function. Specifically, the key findings from the poster demonstrate: With non-internalizing Affimer protein binding and extracellular warhead release by FAP, the AffDC optimizes the bystander effect, leading to effective killing of antigen-positive and antigen-negative tumor cellsAffDCs have an antigen-binding region of 14kDa (single-domain) or 28 kDa (two-domain) that is 10-20% of the size of an antibody, optimizing tumor penetration. AffDCs may be rapidly engineered for optimal biophysical and functional characteristics.The FAP AffDC molecules exhibit a broad range of FAP binding (including potency up to single-digit picomolar, pM) combined with highly tumor-specific warhead release by leveraging the preCISION linker to release warhead directly in the tumor microenvironment and target that delivery to tumors with low FAP expression For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group Communications Directorhttps://avacta.com/Peel Hunt (Nomad and Broker)James Steel / Chris Golden / Patrick Birkholmwww.peelhunt.comICR Consilium Mary-Jane Elliott / Jessica Hodgson / Sukaina Virjiavacta@consilium-comms.com About the pre|CISION® Platform The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. About AVA6000: FAP-enabled doxorubicin The lead pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/. AVA6103: FAP-enabled PDC targeting Topoisomerase I AVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability. AVA7100: pre|CISION® FAP Affimer Drug Conjugate (AffDC) AVA7100 is a pre|CISION®-enabled Affimer® drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer® molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload. About Avacta Group plc - https://avacta.com/ Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION® platform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/.

PDCPhase 1AACR

21 Oct 2024

·www.biospace.com

City of Hope to Present Innovative Research and Treatment Options for Cancer Patients at the 21st International Conference of the Society for Integrative Oncology

The comprehensive cancer center’s experts will spotlight scientific data on how dietary choices, psychosocial support, massage therapy and mind-body calming practices can improve outcomes and the quality of life of people touched by cancer LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States, ranked among the nation’s top 5 cancer centers by U.S. News & World Report and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, will present new data on integrative oncology research and clinical trials at the 21st International Conference of the Society for Integrative Oncology taking place Oct. 25 to 27. Integrative oncology is a patient-centered field of cancer care that combines conventional cancer treatments with complementary, evidence-based therapies to improve outcomes and quality of life. The hybrid conference hosted by City of Hope in Costa Mesa, California, will include more than 170 oral and poster abstracts evaluating supplements and herbal therapies, traditional medicine such as acupuncture, lifestyle choices like diet and exercise, mind-body practices, and use of artificial intelligence and machine learning in integrative oncology. “City of Hope and other experts will share the best science that’s occurring in the field of integrative oncology, which aims to optimize health, quality of life and clinical outcomes,” said Richard T. Lee , M.D., Cherng Family Director’s Chair for the Center for Integrative Oncology at City of Hope, medical director of supportive and integrative medicine at City of Hope Orange County and co-chair of the SIO conference. “City of Hope is leading a national effort to make evidence-based integrative oncology a routine and interwoven part of optimal cancer care and survivorship. City of Hope is bringing together leaders in the field to create the most holistic approach to cancer care.” A $100 million gift from Panda Express Co-CEOs Andrew and Peggy Cherng has enabled City of Hope to lead efforts to accelerate research, therapeutic development and clinical trials for the advancement of evidence-based integrative oncology practices so that cancer patients nationwide and their doctors have access to safe, proven approaches. Some of the leading-edge data City of Hope will present include the following oral abstracts. Massage therapy during infusion lessens the side effects of chemotherapy in a pilot study Presentation time and location: Saturday, Oct. 26 in the Plaza Ballroom from 3 to 4:15 p.m. Christy DiCristofano, a City of Hope massage therapist, led a pilot study assessing the therapeutic effects of massage on cancer patients. The research team surveyed 232 individuals who collectively received 500 hand and/or foot massages while undergoing an infusion. They found that massage therapy is a beneficial additional treatment for symptoms induced by chemotherapy. The therapy had no reported side effects and proved useful in managing symptoms, such as anxiety, pain, shortness of breath, nausea and neuropathy, which is marked by shooting pain, numbness or tingling. Further research is needed to comprehensively evaluate the benefits of this intervention during infusion. Increasing white button mushroom intake could slow the progression of prostate cancer Presentation time and location: Sunday, Oct. 27 in the Lido Room from 10:45 a.m. to noon Bidirectional translational research led by Xiaoqiang Wang, M.D., Ph.D., City of Hope staff scientist, and Shiuan Chen , Ph.D., professor and chair of City of Hope’s Department of Cancer Biology and Molecular Medicine and the Lester M. and Irene C. Finkelstein Chair in Biology, revealed that consuming white button mushrooms can alter androgen levels and boost anti-cancer immunity. The comprehensive research included preclinical experiments, mouse models and prostate cancer patients participating in an ongoing phase 2 clinical trial. The physician-scientists collected blood samples from both mouse models and humans, analyzing myeloid-derived suppressor cells that are responsible for squelching immune responses and assisting tumor growth. They found that consuming white button mushrooms enhances anti-tumor immunity and slows prostate cancer progression. They expect to learn more once the phase 2 clinical trial is completed. Can intermittent fasting decrease the side effects of radiotherapy and enhance its efficacy? Presentation time and location: Friday, Oct. 25 in the Mesa Verde Room from 2:30 to 3:45 p.m. Several clinical and preclinical studies suggest that time-restricted eating, more commonly called intermittent fasting, may enhance anti-tumor response, decrease side effects and improve quality of life during systemic therapy. Ziyi Huang, M.D., City of Hope research fellow, and Yun Rose Li , M.D., Ph.D., assistant professor of radiation oncology at City of Hope, are leading an ongoing randomized phase 2 trial testing whether patients with pelvic malignancies who practice time-restricted eating could experience reduced levels of radiotherapy-induced side effects and enhanced radiotherapy efficacy. The time-restricted eating group are asked to fast for 12 to 14 hours on radiotherapy days. Researchers collect diet logs, stool, urine and blood samples alongside patient- and clinician-reported toxicities. Thus far, the results are encouraging and support the tolerability and feasibility of intermittent fasting during pelvic radiotherapy, especially among patients with prostate cancer. Enrollment in the trial is expected to be completed in spring 2025. Nurses can videoconference cancer patients to provide supportive care and improve quality of life Presentation time and location: Saturday, Oct. 26 in the Plaza Ballroom from 3 to 4:15 p.m. Psychosocial support services can be limited in small urban and rural areas. Up to 70% of patients with advanced cancer experience elevated levels of fear of cancer progression characterized by intrusive thoughts, distress and difficulty making future plans. Anne Reb , Ph.D. N.P., assistant professor of nursing research and education at City of Hope, and Betty Ferrell , Ph.D., M.S.N., CHPN, City of Hope director and professor of nursing research and education, led a pilot study to assess the feasibility and preliminary effects of a nurse-guided videoconferencing intervention to manage fear of cancer progression levels in patients with Stage 3 or 4 gynecologic or lung cancer. Some 82% of the 30 study participants completed all five nurse-led videoconferencing sessions and reported using the tools the nurses introduced like attention training and detached mindfulness to focus, connect with what is most important to them and gain control over daily life stressors. The intervention showed improvement in fear and other quality-of-life outcomes. Feasibility and acceptability was established in this small sample size and suggestions for improvement were established. The potential risk of drug interactions with cannabis use Presentation time and location: Saturday, Oct. 26 in the Plaza Ballroom from 11:30 a.m. to 12:45 p.m. In one of the first studies to assess cannabis-related drug interactions in patients receiving cancer treatment, Elyssa Kim, B.S., former City of Hope research assistant, and Richard T. Lee , M.D., City of Hope clinical professor of supportive and integrative medicine, found that a significant proportion of cannabis users are at risk of moderate to major potential medication interactions. Of the 313 participants, 61 were actively using a form of cannabis to address insomnia (46%), pain (41%) and mood (39%). The most common medications whose effectiveness could be compromised due to cannabis use were noted to be medications for pain or inflammation (acetaminophen, dexamethasone), anti-nausea (ondansetron) and even chemotherapy (paclitaxel, doxorubicin). Researchers say that more states are legalizing cannabis and more cancer patients turn to cannabis to alleviate cancer symptoms, but we need more data on the therapeutic effects and pitfalls of cannabis use during cancer treatment. A mix of mindfulness meditation, gentle exercise and spirituality is linked to improved emotional well-being among breast cancer survivors Presentation time and location: Saturday, Oct. 26 in the Lido Room from 11:30 a.m. to 12:45 p.m. Breast cancer survivors often report experiencing anxiety, depression, poor sleep and cognitive impairment. Frank Munoz, a City of Hope chaplain, conducted a pilot study of meditative movement effects on this patient population, taking blood samples to measure serotonin-related (HTR1F and SLC6A4) and mood/cognitive function-related (BDNF, IL6 and IL1b) gene expression levels. The intervention resulted in a biological change in scores of anxiety, depression, sleep quality and cognitive function. This small study, which demonstrated changes in gene expression, suggests that meditative movement such as tai chi and meditation may help breast cancer survivors recover from persistent mental and emotional symptoms. About City of Hope City of Hope’s mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines , as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™ . For more information about City of Hope, follow us on Facebook , X , YouTube , Instagram and LinkedIn . Contacts Zen Logsdon 626-409-9367 zlogsdon@coh.org

Phase 2

17 Oct 2024

·www.globenewswire.com

Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform

Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform London, Oct. 17, 2024 – Avacta Group plc (AIM: AVCT), a life sciences company developing innovative targeted oncology drugs, today announces the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION®-enabled drug conjugates. Avacta is developing a portfolio of pre|CISION® product candidates that are designed to be activated specifically in the tumor microenvironment, thereby enabling improved antitumor activity while reducing systemic toxicities. The Company has developed a pipeline of peptide drug conjugates, each of which is comprised of an active antitumor drug (known as a payload) linked to the pre|CISION® peptide, which is cleaved only within the tumor by the action of Fibroblast Activation Protein, or FAP. The first of the two new programs is AVA6103, a novel pre|CISION®-enabled peptide drug conjugate comprised of the pre|CISION® peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. This PDC is designed to deliver the exatecan payload directly to tumors while limiting the exposure of the released payload in normal tissues. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. More recently, this payload has been adapted for use in antibody drug conjugates and other approaches. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability. The second program is AVA7100, a pre|CISION®-enabled Affimer® drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer® molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and greater binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload. Christina Coughlin, MD, PhD, Chief Executive Officer of Avacta, commented: “The expansion of our pipeline highlights the broad potential of our proprietary pre|CISION® technology to deliver multiple potent oncology therapeutics directly into difficult-to-treat tumors, while sparing healthy tissues. These novel assets have been carefully selected to complement our existing portfolio, by targeting cancers with high unmet need and having clear development strategies. We look forward to sharing data across our programs in the near future.” Further details of these programs will be released in conjunction with the Company’s two presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Barcelona from October 23-25, 2024. The platform and the pipeline will be presented at the investor and analyst R&D Spotlight Event: Focus on pre|CISION®, in London on October 30, 2024. For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group Communications Director https://avacta.comPeel Hunt (Nomad and Broker)James Steel / Chris Golden / Patrick Birkholm www.peelhunt.comICR Consilium Mary-Jane Elliott / Jessica Hodgson / Sukaina Virjiavacta@consilium-comms.com About the pre|CISION® Platform The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. About AVA6000 The lead pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/ About Avacta Group plc: https://avacta.com/ Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION® platform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

Phase 1

100 Deals associated with Doxorubicin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01275	Doxorubicin Hydrochloride	L01DB01	DB00997

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
AIDS-related Kaposi Sarcoma	JP	Baxter Holdings Ltd. (Japan)	04 Jan 2007
Kaposi Sarcoma	JP	Mochida Pharmaceutical Co., Ltd.	04 Jan 2007
Bone Cancer	JP	Sandoz AG	14 Feb 2005
Childhood Malignant Solid Neoplasm	JP	Sandoz AG	14 Feb 2005
Endometrial Carcinoma	JP	Sandoz AG	14 Feb 2005
Ewing Sarcoma	JP	Sandoz AG	14 Feb 2005
Hepatoblastoma	JP	Sandoz AG	14 Feb 2005
Multiple Myeloma	JP	Sandoz AG	14 Feb 2005
Retinoblastoma	JP	Sandoz AG	14 Feb 2005
Rhabdomyosarcoma	JP	Sandoz AG	14 Feb 2005
Soft Tissue Neoplasms	JP	Sandoz AG	14 Feb 2005
Transitional Cell Carcinoma	JP	Sandoz AG	03 Jan 2004
Lung Cancer	CN	Pfizer Pharmaceutical (Wuxi) Co. Ltd.	01 Jan 2001
Lymphoma	CN	Pfizer Pharmaceutical (Wuxi) Co. Ltd.	01 Jan 2001
Ovarian Cancer	US	Pfizer Inc.	23 Dec 1987
Stomach Cancer	US	Pfizer Inc.	23 Dec 1987
Bladder Cancer	JP	Sandoz AG	22 May 1979
Acute Lymphoblastic Leukemia	US	Pfizer Inc.	07 Aug 1974
Acute Myeloid Leukemia	US	Pfizer Inc.	07 Aug 1974
Breast Cancer	US	Pfizer Inc.	07 Aug 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	NDA/BLA	CN	NATCO Pharma Ltd.	30 Jan 2022
Neoplasms	NDA/BLA	CN	Dr. Reddy's Laboratories Ltd.	30 Jan 2022
Early Stage Breast Carcinoma	Phase 3	DE	Teva Pharmaceuticals USA, Inc.	01 Jul 2014
Recurrent ovarian cancer	Phase 3	CN	Xian Janssen Pharmaceutical Ltd.	01 Jun 2013
Locally advanced breast cancer	Phase 3	-	Sanofi SA	01 Sep 2002
Locally advanced breast cancer	Phase 3	-	Roche Pharma AG	01 Sep 2002
Locally advanced breast cancer	Phase 3	-	Amgen, Inc.	01 Sep 2002
Ovarian Epithelial Carcinoma	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 May 1997
Ovarian Epithelial Carcinoma	Phase 3	-	SEQUUS Pharmaceuticals, Inc.	01 May 1997
Classical Hodgkin's Lymphoma	Phase 2	US	Seagen Inc.	14 Dec 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05261490 (C4971002, CTgov)	Phase 2	Primary peritoneal carcinoma \| Ovarian Epithelial Carcinoma \| Platinum-Resistant Ovarian Carcinoma ... View more	10	Maplirpacept (PF-07901801) (Phase 1: Maplirpacept (PF-07901801) 12 mg/kg + PLD)	czkiohbjex(vyahlhtnue) = ivwmjcwskg yiduuafayc (mrzfajhvxz, uuciksiegm - sboalosavn) View more	-	31 Oct 2024
				Maplirpacept (PF-07901801) (Phase 1: Maplirpacept (PF-07901801) 24 mg/kg + PLD)	czkiohbjex(vyahlhtnue) = oqkgsklpqq yiduuafayc (mrzfajhvxz, reskxskyzc - stymdpfgwy) View more
NCT02641847 (BCTOP-T-A01, Literature) Manual	Phase 3	Triple Negative Breast Cancer	498	docetaxel+doxorubicin or epirubicin+cyclophosphamide+gemcitabine+cisplatin (High risk group A)	kurhnrekwy(wofemwupqh) = mckszkcbyi srioijarct (vjlxmbszjm ) View more	Positive	23 Oct 2024
				docetaxel+doxorubicin or epirubicin+cyclophosphamide (High risk group B)	kurhnrekwy(wofemwupqh) = ldqtaywujs srioijarct (vjlxmbszjm ) View more
NCT03907488 (S1826, Pubmed) Manual	Phase 3	Classical Hodgkin's Lymphoma	994	Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD)	skwgveaoir(usbmynonra) = rzmyljuwcx pubdrezheb (izmgyyyyet, 79 - 86)	Positive	17 Oct 2024
				Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)	skwgveaoir(uoilkijupx) = zpegdhowhy mghpzsoleo (zkwkoarftd ) View more
NCT01678664 (EVACEL \| FFCD 1104-EVACEL-GTE, CTgov)	Phase 2	Liver metastases \| Endocrine Gland Neoplasms \| Neuroendocrine Tumors	74	embolization+Doxorubicin+Everolimus	zmfspnmhtf(kyaeqllyar) = fwonlrtulc zslhbwvqqn (xdvdgqqxli, wfniaxurgz - inddsslykw) View more	-	25 Sep 2024
NCT04535713 (gallant, ESMO2024) Manual	Phase 2	Sarcoma Second line	76	Metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab	kpzvomhmny(ruaulnlegj) = jwrdynaboa qqtwkbtcef (eazqfcdhph, 6.4 - 10.0) View more	Positive	14 Sep 2024
ESMO2024 Manual	Not Applicable	Aggressive Fibromatosis First line	29	Pegylated liposomal doxorubicin (PLD) 40 mg/m2	pekxxlvdnw(mihykspgjd) = ohcecmfsqs vszvuexnsg (vdjobxhzde ) View more	Positive	14 Sep 2024
NCT02997358 (LMS04, Pubmed \| N Engl J Med) Manual	Phase 3	Leiomyosarcoma Maintenance \| First line	150	Doxorubicin+Trabectedin	(isgxesdexi) = grprykchuj befybpvfjj (mzqsqjjipx, 10 - 16) View more	Positive	05 Sep 2024
				Doxorubicin	(isgxesdexi) = btdhhhguzj befybpvfjj (mzqsqjjipx, 4 - 7) View more
NCT03960008 (SBRTvsTACE, CTgov)	Phase 3	Hepatocellular Carcinoma	9	Stereotactic Body Radiation Therapy (SBRT) (Stereotactic Body Radiation Therapy (SBRT))	dwlijcgynl(emtmedpxqk) = vcqospwzfb ppgcuunqpz (xijrirgdku, aiukbwjtzn - pxalflnzyh) View more	-	28 Aug 2024
				Trans-Arterial Chemoembolization (TACE)+Doxorubin (Trans-Arterial Chemoembolization (TACE))	dwlijcgynl(emtmedpxqk) = rarbjtxyip ppgcuunqpz (xijrirgdku, ocsjfkhryz - zpkmtuabcd) View more
NCT03792256 (CTgov)	Phase 1	Recurrent Adult Acute Lymphoblastic Leukemia \| T-Cell Lymphoma \| acute leukemia ... View more	12	ARAC (Stratum 1 With 50 mg/m^2)	gxyihepucw(rqlhdrooxw) = zczqzuugly fygaqdhera (rommrswdnu, sduugvmjci - isuuetrewz) View more	-	16 Aug 2024
				ARAC (Stratum PK With 50 mg/m^2)	gxyihepucw(rqlhdrooxw) = ztmhvynpkd fygaqdhera (rommrswdnu, ruygbbzwcm - rvzxjdddrt) View more
NCT04213612 (Pubmed)	Phase 1	Relapsed Solid Neoplasm	34	Pegylated liposomal doxorubicin (PLD) 30 mg/m2	dbyiefotfo(foysaxqiyx) = ykeclpgbev wgzhjhskry (jjjjhtotfv ) View more	Positive	01 Jul 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis